Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Myriad Genetics announced the publication of the analytical validation of the FirstGene® Multiple Prenatal Screen in Clinical Chemistry.
-
Myriad will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026.
-
Myriad advances Precise MRD toward a March 2026 launch, backed by new breast and colorectal cancer data showing ultrasensitive ctDNA detection.
-
Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.
-
Sam Raha, president and CEO of Myriad, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 14, at 5:15 pm PT.
-
Myriad Genetics will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS).
-
Clairity, Myriad Genetics, and MagView announce a joint collaboration in an effort to identify more women at high risk for breast cancer.
-
Myriad Genetics management will participate in two upcoming healthcare conferences.
-
Myriad Genetics expanded MyRisk® Hereditary Cancer Test to include genes referenced in national oncology guidelines.
-
Myriad Genetics will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at NSGC.